Background: Knee osteoarthritis (KOA) is a degenerative joint disorder marked by cartilage degradation, synovial inflammation, and altered synovial fluid (SF) rheology, resulting in pain and impaired joint function. Intra-articular hyaluronic acid (IA-HA) injections aim to restore SF viscoelasticity and improve lubrication; however, their efficacy may be potentiated when combined with physiotherapy (PT). This monocentric observational study evaluated whether the addition of a multimodal PT program to IA-HA therapy enhances SF rheologic properties compared to IA-HA alone. Methods: A total of 52 patients (aged 47–61) with radiographically confirmed moderate KOA (Kellgren–Lawrence grade 2) were enrolled. Patients were assigned to a pilot group (PG; n = 37) receiving IA-HA (Kombihylan^®, 3 MDa) combined with a multimodal PT protocol, or a control group (CG; n = 15) receiving IA-HA alone. The PT program included ten sessions of transcutaneous electrical nerve stimulation, low-level laser therapy, therapeutic ultrasound, progressive exercise, and cryotherapy. SF samples were collected immediately after the first injection and again at six weeks, then analyzed rheologically using the Kinexus Pro+ rheometer. Viscosity parameters were assessed via steady and oscillatory shear tests. Results: At baseline, both groups demonstrated comparable SF viscosity profiles. After six weeks, the PG exhibited significantly higher shear viscosity values across all measured percentiles and reduced variability in rheological parameters, suggesting a more stable intra-articular milieu. Rheometric analysis indicated enhanced SF viscoelasticity, potentially mediated by reduced inflammation and stimulation of endogenous HA synthesis. In contrast, the CG showed inconsistent viscosity changes, reflecting variable responses to IA-HA monotherapy. Conclusions: Combining IA-HA with multimodal PT significantly improves SF rheological properties in moderate KOA patients compared to IA-HA alone. These findings support the role of mechanical stimulation in enhancing joint lubrication and homeostasis, offering a more consistent and effective approach to viscosupplementation.

Cardiac telerehabilitation has become a promising alternative to traditional programmes for preventing acute coronary syndrome (ACS) in the secondary phase. However, current implementations are still reactive and standardised, lacking personalisation and flexibility in clinical settings. By integrating artificial intelligence (AI), it may be possible to overcome these limitations and provide intelligent, scalable, and patient-centred care. Methods: We conducted a structured literature review across PubMed, Scopus, the Cochrane Library, and Web of Science, targeting English-language studies published from January 2015 to May 2025. Inclusion criteria included adult populations with a history of ACS or high cardiovascular risk, assessing interventions based on AI, telerehabilitation, or their combination. Studies are needed to report clinical, functional, behavioural, or technological outcomes. A thematic narrative synthesis was utilised. Results: AI-enhanced telerehabilitation demonstrates potential advantages over conventional digital care in selected domains, including adaptive risk prediction, personalised exercise modulation, and adherence support. Several systems report real-time adjustment of exercise protocols, early dropout detection, and predictive analytics for rehospitalisation. AI integration may also contribute to personalised behavioural feedback and psychosocial monitoring. Nevertheless, the overall level of evidence remains preliminary and heterogeneous, with most AI-based interventions evaluated in pilot, feasibility, or modelling studies rather than large-scale randomized trials. Conclusions: The integration of AI into telerehabilitation represents a promising evolution in post-ACS care, shifting from predominantly reactive monitoring toward more adaptive and data-driven support models. While early-phase studies suggest feasibility and potential clinical benefit, robust multicentre randomized controlled trials and cost-effectiveness analyses are required before definitive conclusions regarding superiority or widespread implementation can be drawn.